report cover1

Global Primary Progressive Multiple Sclerosis Treatment Market"(By Treatment Type: Disease-Modifying Therapies, Symptom Management Medications, Rehabilitation Therapies); (By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)”- Industry Analysis, Size, Share, Growth, Trends, And Forecast, 2022-2030

A prominent research firm, Cognizance Market Research added an innovative industry report on the ” Global Primary Progressive Multiple Sclerosis Treatment Market”. The report studies the current as well as past growth trends and opportunities for the market to gain valuable insights during the forecast period from 2022 to 2030.

Global Primary Progressive Multiple Sclerosis Treatment Market Analysis:

According to cognizance market research, the Global primary progressive multiple sclerosis treatment market was valued at US$ 994.3 million in 2022 and is anticipated to reach US$ 3,012.8 million by the end of 2030 expected to register a CAGR of 14.9% from 2023 to 2030.

primary progressive multiple sclerosis treatment market

What is Global Primary Progressive Multiple Sclerosis Treatment Market?

The market for drugs and therapies used to treat patients with primary progressive multiple sclerosis (PPMS) refers to the market for drugs and therapies used to treat patients with PPMS, a type of multiple sclerosis (MS) characterised by a steady progression of neurological symptoms without the occurrence of relapses. PPMS affects a lesser proportion of MS patients than other types of the illness, such as RRMS and SPMS, but it is linked with more severe impairment and a greater burden on patients and carers.

Disease-modifying treatments (DMTs), symptom management medications, and supportive therapies are among the pharmaceuticals and therapies available in the PPMS therapeutic market. DMTs are medications that are intended to change the fundamental course of the illness and reduce its progression, whilst symptom management therapies are used to treat PPMS symptoms such as spasticity and exhaustion. Physical therapy and occupational therapy, for example, are crucial components of the total treatment of PPMS.

The PPMS treatment market is expanding because of the disease’s rising prevalence, the discovery of novel medications and therapies, and the use of digital health technologies that improve patient outcomes and access to care. As the market evolves, new possibilities for medication developers, healthcare providers, and other stakeholders to enhance the lives of people with PPMS are expected to appear.

PPMS is a very uncommon variant of multiple sclerosis (MS), accounting for only around 10-15% of all MS cases. PPMS often affects elderly people at the time of diagnosis, with symptoms that deteriorate with time without remission. PPMS, unlike other types of MS, is distinguished by a constant and progressive loss in neurological function with no relapses.

The precise aetiology of PPMS is unknown, although it is thought to be an autoimmune reaction in which the body’s immune system assaults the myelin sheath that covers and protects nerve fibres in the central nervous system. As myelin is damaged, nerve fibres are also injured or destroyed, resulting in a variety of symptoms such as muscular weakness, coordination and balance issues, and vision, speech, and cognition issues.

As our understanding of the underlying processes of PPMS grows and new medications and therapies are researched and evaluated, there is optimism that improved treatments will become accessible to help individuals with this severe condition.

Global Primary Progressive Multiple Sclerosis Treatment Market Outlook:

The primary progressive multiple sclerosis (PPMS) treatment market is predicted to expand in the next years, driven by factors such as increasing illness prevalence, increased disease awareness, and the discovery of novel medications and therapies. However, the industry confronts significant hurdles, including high treatment costs, limited therapy options for PPMS patients, and the lack of a cure for the condition.

The rising incidence of the condition is one of the primary drivers of the PPMS therapy industry. According to the National Multiple Sclerosis Society, PPMS affects around 15% of MS patients and is projected to rise as the population ages. This expanding patient population will boost demand for novel and effective PPMS therapies.

Another important market driver is rising illness knowledge and comprehension. As more knowledge about the origins and symptoms of PPMS becomes accessible, healthcare practitioners and patients will be better equipped to find and manage the condition. This greater awareness is also fuelling the need for new and more effective therapies.

The excessive cost of therapy is one of the primary difficulties confronting the PPMS treatment market. Many of the medicines and treatments used to treat PPMS are costly, making them out of reach for many patients. This excessive cost also serves as a barrier to the development of novel treatments and cures since drug developers may be unwilling to spend in R&D for a market with low-income potential.

Despite these obstacles, the PPMS therapy business offers several prospects for expansion. The creation of novel pharmaceuticals and therapies is one of the most important opportunities. For example, in March 2021, Biogen won FDA clearance for aducanumab, the first medication to target the underlying pathology of Alzheimer’s disease. While this medicine is not targeted at PPMS, it proves the possibility for novel therapies that can target the fundamental causes of neurological illnesses to be created.

The adoption of digital health technology is another avenue for expansion. Telemedicine and mobile health applications, for example, can aid PPMS patients gain access to therapy, save expenses, and improve patient outcomes. Research published in the Journal of Telemedicine and Telecare, for example, discovered that telemedicine can be a useful technique for giving physical therapy to individuals with PPMS.

Segment Analysis:

The market for primary progressive multiple sclerosis (PPMS) therapies is divided into three categories: medication type, distribution channel, and geography.

The market can be further divided into immunosuppressants, monoclonal antibodies, and others based on medication type. Because of their excellent effectiveness in treating PPMS, monoclonal antibodies are projected to be the dominating sector. In PPMS patients, monoclonal antibodies such as ocrelizumab and alemtuzumab have been proven to reduce the course of impairment. Immunosuppressants are also predicted to develop rapidly, owing to increased usage of medications such as mitoxantrone and cyclophosphamide.

Immunosuppressants: These medications lower the intensity of symptoms and limit the course of the disease by inhibiting the immune system. Mitoxantrone, cyclophosphamide, and azathioprine are sub-segments in this group.

Monoclonal antibodies: These medications function by targeting certain immune system cells to decrease inflammation and halt disease development. This category’s sub-segments include ocrelizumab, alemtuzumab, and rituximab.

Others: This category has medications that do not fall into the categories of immunosuppressants or monoclonal antibodies, such as interferon beta-1a and glatiramer acetate. These medications act by changing the immune system to minimise inflammation and halt disease development.

The market may be further categorised based on distribution channels into hospital pharmacies, retail pharmacies, and internet pharmacies. Because the majority of PPMS patients are treated in hospitals or other healthcare facilities, the hospital pharmacy sector is projected to be the market leader. The online pharmacy industry, on the other hand, is predicted to increase at a quicker rate, owing to the growing popularity of online purchasing and the convenience provided by online pharmacies.

Monoclonal antibodies are predicted to be the fastest-expanding sector in the PPMS therapy market.

Geographical Analysis:

Based on geography the global primary progressive multiple sclerosis treatment market has been segmented into five main regions namely, North America, Asia Pacific, Europe, Latin America, and Middle East & Africa.

Because of the high incidence of the condition in the region, well-established healthcare infrastructure, and the presence of large pharmaceutical firms, North America is likely to be the dominant market for PPMS therapy. According to the National Multiple Sclerosis Society, around 1 million people in the United States have multiple sclerosis (MS), and roughly 15% of them have PPMS. Furthermore, the availability of sophisticated diagnostic and treatment facilities is likely to fuel the growth of the North American PPMS treatment market.

Europe is predicted to be the second largest market for PPMS therapy, owing to the region’s high illness awareness and comprehension, well-established healthcare infrastructure, and the presence of significant pharmaceutical firms. According to the European Multiple Sclerosis Platform, there are around 700,000 persons living with MS in Europe, with PPMS accounting for approximately 10% of them. Furthermore, the increased use of improved treatment alternatives, as well as the availability of reimbursement policies, are projected to boost the growth of the European PPMS treatment market.

Due to the increasing frequency of MS in the region, rising healthcare spending, and the availability of a large patient pool, Asia Pacific is predicted to be the fastest-expanding market for PPMS therapy. According to Grand View Research, the prevalence of MS in Asia is rising at a pace of 3-5 per cent each year, and the region is projected to have 30,000-40,000 people living with the disease. Furthermore, the growing emphasis on the creation of modern healthcare facilities, as well as the availability of low-cost treatment choices, are likely to support the growth of the Asia Pacific PPMS treatment market.

In terms of the leading and fastest-increasing segments in each region, monoclonal antibodies are predicted to be the leading and fastest-expanding segment across all regions. This is due to the great efficacy of these medications in treating PPMS, as well as the growing acceptance of modern treatment choices.

geographical analysis


The report offers the revenue of the global primary progressive multiple sclerosis treatment market for the period 2020-2030, considering 2020 & 2021 as a historical years, 2022 as the base year and 2023 to 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global primary progressive multiple sclerosis treatment market for the forecast period. The global primary progressive multiple sclerosis treatment market report provides insights and in-depth analysis into developments impacting enterprises and businesses on a regional and global level. The report covers the global primary progressive multiple sclerosis treatment market performance in terms of revenue contribution from several segments and comprises a detailed analysis of key drivers, trends, restraints, and opportunities prompting revenue growth of the global primary progressive multiple sclerosis treatment market.

The report has been prepared after wide-ranging secondary and primary research. Secondary research included internet sources, numerical data from government organizations, trade associations, and websites. Analysts have also employed an amalgamation of bottom-up and top-down approaches to study numerous phenomena in the global primary progressive multiple sclerosis treatment market. Secondary research involved a detailed analysis of significant players’ product portfolios. Literature reviews, press releases, annual reports, white papers, and relevant documents have been also studied to understand the global primary progressive multiple sclerosis treatment market. Primary research involved a great extent of research efforts, wherein experts conducted interviews telephonic as well as questioner-based with industry experts and opinion-makers.

The report includes an executive summary, along with a growth pattern of different segments included in the scope of the study. The Y-o-Y analysis with elaborate market insights has been provided in the report to comprehend the Y-o-Y trends in the global primary progressive multiple sclerosis treatment market. Additionally, the report focuses on altering competitive dynamics in the global market. These indices serve as valued tools for present market players as well as for companies interested in participating in the global primary progressive multiple sclerosis treatment market. The subsequent section of the global primary progressive multiple sclerosis treatment market report highlights the USPs, which include key industry events (Type launch, research partnership, acquisition, etc.), technology advancements, pipeline analysis, prevalence data, and regulatory scenario.

Global Primary Progressive Multiple Sclerosis Treatment Market Competitive Landscape:

The market for primary progressive multiple sclerosis (PPMS) therapies is extremely competitive, with numerous established businesses as well as new entrants fighting for market dominance. To preserve their market position, the industry’s top companies are focused on creating innovative medicines and extending their geographical presence. The following companies are important participants in the PPMS treatment market:

  • Biogen Inc.
  • Novartis AG
  • Roche Holding AG
  • Sanofi S.A.
  • Merck & Co. Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Bayer AG
  • Eisai Co., Ltd.
  • GlaxoSmithKline plc
  • Genentech, Inc.
  • Mylan N.V.
  • Johnson & Johnson Services, Inc.
  • Actelion Pharmaceuticals Ltd.
  • Acorda Therapeutics, Inc.
  • Alexion Pharmaceuticals, Inc.
  • Alkermes plc
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Biota Pharmaceuticals, Inc.
  • Celgene Corporation
  • Chugai Pharmaceutical Co., Ltd.
  • Daiichi Sankyo Company, Limited

To increase their research and development skills and grow their product line, these firms are focused on collaborations and partnerships with other companies, academic institutes, and government agencies. Biogen and Eisai Co., Ltd., for example, announced an agreement in March 2021 to jointly develop and market two clinical-stage experimental medicines, including an anti-Tau antibody for the treatment of Alzheimer’s disease and other neurodegenerative illnesses.

Companies are also investing in new product releases and advancements to keep their market leadership. For example, Novartis AG got permission from the US Food and Medicine Administration (FDA) in May 2020 for its drug Mayzent (siponimod) for the treatment of PPMS. This medicine is the first and only FDA-approved therapy for PPMS, giving Novartis a considerable market advantage.

Furthermore, corporations are working on mergers and acquisitions to extend their market presence and product offers. For example, Roche Holding AG completed the purchase of Spark Therapeutics, a prominent gene therapy business, in May 2019 to extend its gene therapy portfolio and improve its position in the neurology market.

The report explores the competitive scenario of the global primary progressive multiple sclerosis treatment market. Major players working in the global primary progressive multiple sclerosis treatment market have been named and profiled for their unique commercial attributes. Company overview (company description, Type portfolio, geographic presence, employee strength, Key management, etc.), financials, SWOT analysis, recent developments, and key strategies are some of the features of companies profiled in the global primary progressive multiple sclerosis treatment market report.


Global Primary Progressive Multiple Sclerosis Treatment Market, By Treatment Type:

  • Disease-Modifying Therapies
  • Symptom Management Medications
  • Rehabilitation Therapies

Global Primary Progressive Multiple Sclerosis Treatment Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Global primary progressive multiple sclerosis treatment market, by region:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia & New Zealand
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of the Middle East & Africa
Complete the form below and we'll get back to you shortly
Table of Content

Research Methodology: Aspects

Market research is a crucial tool for organizations aiming to navigate the dynamic landscape of customer preferences, business trends, and competitive landscapes. At Cognizance Market Research, acknowledging the importance of robust research methodologies is vital to delivering actionable insights to our clientele. The significance of such methodologies lies in their capability to offer clarity in complexity, guiding strategic management with realistic evidence rather than speculation. Our clientele seek insights that excel superficial observations, reaching deep into the details of consumer behaviours, market dynamics, and evolving opportunities. These insights serve as the basis upon which businesses craft tailored approaches, optimize product offerings, and gain a competitive edge in an ever-growing marketplace.

The frequency of information updates is a cornerstone of our commitment to providing timely, relevant, and accurate insights. Cognizance Market Research adheres to a rigorous schedule of data collection, analysis, and distribution to ensure that our reports reflect the most current market realities. This proactive approach enables our clients to stay ahead of the curve, capitalize on emerging trends, and mitigate risks associated with outdated information.

Our research process is characterized by meticulous attention to detail and methodological rigor. It begins with a comprehensive understanding of client objectives, industry dynamics, and research scope. Leveraging a combination of primary and secondary research methodologies, we gather data from diverse sources including surveys, interviews, industry reports, and proprietary databases. Rigorous data analysis techniques are then employed to derive meaningful insights, identify patterns, and uncover actionable recommendations. Throughout the process, we remain vigilant in upholding the highest standards of data integrity, ensuring that our findings are robust, reliable, and actionable.

Key phases involved in in our research process are mentioned below:


Understanding Clients’ Objectives:

Extensive Discussions and Consultations:

  • We initiate in-depth discussions and consultations with our clients to gain a comprehensive understanding of their objectives. This involves actively listening to their needs, concerns, and aspirations regarding the research project.
  • Through these interactions, we aim to uncover the underlying motivations driving their research requirements and the specific outcomes they hope to achieve.

Industry and Market Segment Analysis:

  • We invest time and effort in comprehensively understanding our clients’ industry and market segment. This involves conducting thorough research into market trends, competitive dynamics, regulatory frameworks, and emerging opportunities or threats.
  • By acquiring a deep understanding of the broader industry landscape, we can provide context-rich insights that resonate with our clients’ strategic objectives.

Target Audience Understanding:

  • We analyze our clients’ target audience demographics, behaviors, preferences, and needs to align our research efforts with their consumer-centric objectives. This entails segmenting the audience based on various criteria such as age, gender, income level, geographic location, and psychographic factors.
  • By understanding the nuances of the target audience, we can tailor our research methodologies to gather relevant data that illuminates consumer perceptions, attitudes, and purchase intent.


Identifying Challenges and Opportunities:

  • We proactively identify the challenges and opportunities facing our clients within their respective industries. This involves conducting SWOT (Strengths, Weaknesses, Opportunities, Threats) analyses and competitive benchmarking exercises.
  • By identifying potential obstacles and growth drivers, we can provide strategic recommendations that help our clients navigate complexities and capitalize on emerging opportunities effectively.

Grasping Specific Goals:

  • We delve into the intricacies of our clients’ objectives to gain clarity on the specific goals they aim to accomplish through the research. This entails understanding their desired outcomes, such as market expansion, product development, or competitive analysis.
  • By gaining a nuanced understanding of our clients’ goals, we can tailor our research approach to address their unique challenges and opportunities effectively.

Data Collection:


Primary Research Process:

  • Surveys: We design and administer surveys tailored to capture specific information relevant to our clients’ objectives. This may involve employing various survey methodologies, such as online, telephone, or face-to-face interviews, to reach target audiences effectively.
  • Interviews: We conduct structured or semi-structured interviews with key stakeholders, industry experts, or target consumers to gather in-depth insights and perspectives on relevant topics. These interviews allow us to probe deeper into specific issues and uncover valuable qualitative data.
  • Focus Groups: We organize focus group discussions with carefully selected participants to facilitate interactive discussions and gather collective opinions, attitudes, and preferences. This qualitative research method provides rich contextual insights into consumer behaviors and perceptions.
  • Observations: We conduct observational research by directly observing consumer behaviors, interactions, and experiences in real-world settings. This method enables us to gather objective data on consumer actions and reactions without relying on self-reported information.

Secondary Research Process:

  • Literature Review: We conduct comprehensive literature reviews to identify existing studies, academic articles, and industry reports relevant to the research topic. This helps us gain insights into previous research findings, theoretical frameworks, and best practices.
  • Industry Reports: We analyze industry reports published by reputable trade associations (whitepapers, research studies, etc.), and government agencies (U.S. Census Bureau, Bureau of Labor Statistics, and Securities and Exchange Commission etc.) to obtain macro-level insights into market trends, competitive landscapes, and industry dynamics.
  • Government Publications: We review government publications, such as economic reports, regulatory documents, and statistical databases, to gather relevant data on demographics, market size, consumer spending patterns, and regulatory frameworks.
  • Online Databases: We leverage online databases, such as industry portals, and academic repositories (PubMed Central (PMC), ScienceDirect, SSRN (Social Science Research Network), Directory of Open Access Journals (DOAJ), NCBI, etc.), to access a wide range of secondary data sources, including market statistics, financial data, and industry analyses.





Data Analysis:

The data analysis phase serves as a critical juncture where raw data is transformed into actionable insights that inform strategic decision-making. Through the utilization of analytical methods such as statistical analysis and qualitative techniques like thematic coding, we uncover patterns, correlations, and trends within the data. By ensuring the integrity and validity of our findings, we strive to provide clients with accurate and reliable insights that accurately reflect the realities of the market landscape.



Transformation of Raw Data:

  • Upon collecting the necessary data, we transition into the data analysis phase, where raw data is processed and transformed into actionable insights. This involves organizing, cleaning, and structuring the data to prepare it for analysis.

Utilization of Analytical Methods:

  • Depending on the research objectives, we employ a diverse range of analytical methods to extract meaningful insights from the data. These methods include statistical analysis, trend analysis, regression analysis, and qualitative coding.

Statistical Analysis:

  • Statistical tools are instrumental in uncovering patterns, correlations, and trends within the data. By applying statistical techniques such as descriptive statistics, hypothesis testing, and multivariate analysis, we can discern relationships and derive valuable insights.

Qualitative Analysis Techniques:

  • In addition to quantitative analysis, we leverage qualitative analysis techniques to gain deeper insights from qualitative data sources such as interviews or open-ended survey responses. One such technique is thematic coding, which involves systematically categorizing and interpreting themes or patterns within qualitative data.

Integrity and Validity Maintenance:

  • Throughout the analysis process, we maintain a steadfast commitment to upholding the integrity and validity of our findings. This entails rigorous adherence to established methodologies, transparency in data handling, and thorough validation of analytical outcomes.

Data Validation:

The final phase of our research methodology is data validation, which is essential for ensuring the reliability and credibility of our findings. Validation involves scrutinizing the collected data to identify any inconsistencies, errors, or biases that may have crept in during the research process. We employ various validation techniques, including cross-referencing data from multiple sources, conducting validity checks on survey instruments, and seeking feedback from independent experts or peer reviewers. Additionally, we leverage internal quality assurance protocols to verify the accuracy and integrity of our analysis. By subjecting our findings to rigorous validation procedures, we instill confidence in our clients that the insights they receive are robust, reliable, and trustworthy.


Importance of Data Validation:

  • Data validation is the final phase of the research methodology, crucial for ensuring the reliability and credibility of the findings. It involves a systematic process of reviewing and verifying the collected data to detect any inconsistencies, errors, or biases.

Scrutiny of Collected Data:

  • The validation process begins with a thorough scrutiny of the collected data to identify any discrepancies or anomalies. This entails comparing data points, checking for outliers, and verifying the accuracy of data entries against the original sources.

Validation Techniques:

  • Various validation techniques are employed to ensure the accuracy and integrity of the data. These include cross-referencing data from multiple sources to corroborate findings, conducting validity checks on survey instruments to assess the reliability of responses, and seeking feedback from independent experts or peer reviewers to validate the interpretation of results.

Internal Quality Assurance Protocols:

  • In addition to external validation measures, internal quality assurance protocols are implemented to further validate the accuracy of the analysis. This may involve conducting internal audits, peer reviews, or data validation checks to ensure that the research process adheres to established standards and guidelines.

Report Scope:



Market Size

US$ 3,012.8 Million (2030)

Compound Annual Growth Rate (CAGR)


Base Year


Forecast Period


Forecast Units

Value (US$ Million)

Report Coverage

Revenue Forecast, Competitive Landscape, Growth Factors, and Trends

Geographies Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Countries Covered

U.S., Canada, Germany, U.K., France, Spain, Italy, Rest of Europe, Japan, China, India, Australia & New Zealand, South Korea, Rest of Asia Pacific, Brazil, Mexico, Rest of Latin America, GCC, South Africa, Rest of Middle East & Africa

Key Companies Profiled

Biogen Inc., Novartis AG, Roche Holding AG, Sanofi S.A., Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., AbbVie Inc., Bristol-Myers Squibb Company, Bayer AG, Eisai Co., Ltd., GlaxoSmithKline plc, Genentech, Inc., Mylan N.V., Johnson & Johnson Services, Inc., Actelion Pharmaceuticals Ltd., Acorda Therapeutics, Inc., Alexion Pharmaceuticals, Inc., Alkermes plc, Amgen Inc., Astellas Pharma Inc., Biota Pharmaceuticals, Inc., Celgene Corporation, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited

Key Questions Answered in Primary Progressive Multiple Sclerosis Treatment Market Report

The Global Primary Progressive Multiple Sclerosis Treatment Market was valued at US$ 994.3 million in 2022 and is anticipated to reach US$ 3,012.8 million by the end of 2030 expected to register a CAGR of 14.9% from 2023 to 2030.

The rising incidence of PPMS, innovations in treatment choices, and greater awareness among patients and healthcare professionals are driving market expansion. High treatment costs and restricted availability of medicines are two factors limiting expansion.

The discovery of innovative therapies, as well as increasing expenditure in research & development, are key developments in the PPMS treatment industry.

Biogen, Novartis, Roche, and Sanofi are among the market leaders in PPMS therapy. Partnerships, collaborations, and mergers and acquisitions are among the strategies used by these companies.

Disease-modifying therapy, symptom management drugs, and rehabilitative therapies are among the treatment possibilities for PPMS. The availability and effectiveness of the therapy influence adoption rates.

Single User - $4,600.00

It allows one person, the buyer, to have the sole rights and access to the purchased report. Further distribution of the product is strictly prohibited.

It allows the purchased product to be shared among 1-7 employees of your organization within the same geographical location.

It allows the purchased product to be shared among all employees of your organization irrespective of their geographical location.

Need a Custom Report?

We can customize every report – free of charge – including purchasing stand-alone sections or country-level reports

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Business Development

small c popup.png
Complete the form below and we'll get back to you shortly
small c popup.png
Complete the form below and we'll get back to you shortly
small c popup.png
Complete the form below and we'll get back to you shortly
Ask an Expert